Shares of biotech firm WuXi tumble on big rise in capital spending

WuXi PharmaTech Cayman, a Chinese biotechnology company, fell the most in nine months in New York on Friday after its capital spending forecast exceeded estimates and Goldman Sachs cut the stock to neutral from buy.

via South China Morning Post - Business feed http://ift.tt/1x7CjUL